In a bid to become more transparent, the Food and Drug Administration is launching a program to determine the benefits of disclosing certain summaries of clinical trial data, a notion that has evoked long-standing debate over patient privacy, trade secrets, and improving medical research.

The program will release so-called clinical study reports, which contain summary information and analysis, from up to nine different applications filed by companies that seek to market new prescription drugs. The agency plans to rely on drug makers to volunteer to participate.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

  • The only advantage this would provide is to competitors to give them a nice roadmap. It’s a copycat industry. When I started developing a new drug the first thing I requested was the SBA, or summary basis of approval. Now all you have to do is google Drugs at FDA, look up the drug of interest and you will find the complete medical review, usually within 30 days of approval. Single study reports may misleading. If you want some meat before approval make available the ISE (Integrated Summary of Efficacy) and the ISS (Integrated Summary of Safety), which have to be completed by the drug company before the NDA is submitted.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy